EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Advancing clinical response against glioblastoma: Evaluating SHP1705 CRY2 activator efficacy in preclinical models and safety in phase I trials

Priscilla Chan iD, Yoshiko Nagai, Qiulian Wu, Anahit Hovsepyan, Seda Mkhitaryan, Jiarui Wang, Gevorg Karapetyan, Theodore Kamenecka, Laura A Solt, Jamie Cope, Rex A Moats, Tsuyoshi Hirota iD und 2 weitere

Neuro-Oncology · 2025

DOI: 10.1093/neuonc/noaf089 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuro-Oncology, 2025. Verfasst von Priscilla Chan und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Keck School of Medicine, University of Southern California, Los Angeles, California, USA. Hauptthemen laut MEDLINE: Glioblastoma, Cryptochromes, Brain Neoplasms. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Japan Society for the Promotion of Science, NINDS NIH HHS, Astellas Foundation for Research on Metabolic Disorders.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

It has been reported that circadian clock components, Brain and Muscle ARNT-Like 1 (BMAL1) and Circadian Locomotor Output Cycles Kaput (CLOCK), are essential for glioblastoma (GBM) stem cell (GSC) biology and survival. Consequently, we developed a novel Cryptochrome (CRY) activator SHP1705, which inhibits BMAL1-CLOCK transcriptional activity.

Methods

We utilized GlioVis to determine which circadian genes are differentially expressed in non-tumor versus GBM tissues. We employed in vitro and in vivo methods to test the efficacy of SHP1705 against patient-derived GSCs and xenografts in comparison to earlier CRY activator scaffolds. We applied a novel REV-ERB agonist SR29065, which inhibits BMAL1 transcription, to determine whether targeting both negative limbs of the circadian transcription-translation feedback loop (TTFL) would yield synergistic effects against various GBM cells.

Results

SHP1705 is the first circadian clock-modulating compound to be found safe and well-tolerated in Phase I clinical trials. SHP1705 has increased selectivity for the CRY2 isoform and potency against GSC viability compared to previously published CRY activators, making it promising for applications in GBM where CRY2 levels are found to be low. SHP1705 prolonged survival in mice bearing GBM tumors established with GSCs. When combined with novel REV-ERB agonist SR29065, SHP1705 displayed synergy against multiple GSC lines and differentiated GSCs (DGCs).

Conclusions

We demonstrate the efficacy of SHP1705 against GSCs, which pose as a major source of chemoradiation resistance leading to poor GBM patient prognosis. Novel circadian clock compounds have high potential for targeting GBM as single agents or in combination with each other or current standard-of-care.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaCryptochromesBrain NeoplasmsAnimalsHumansMiceXenograft Model Antitumor AssaysTumor Cells, CulturedFemaleCell ProliferationCircadian Clocks

Stichwörter der Autor:innen

CRY2SHP1705circadian clockcircadian medicineglioblastoma

Substanzen

CryptochromesCRY2 protein, human

Autor:innen und Institutionen

  • Department of Neurology, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
  • Institute of Transformative Bio-Molecules (WPI-ITbM), Nagoya University, Furo-cho, Chikusa-ku, Nagoya, Japan.
  • Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
  • Small Animal Imaging Core, Department of Radiology, Children's Hospital Los Angeles, California, USA.
  • The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology, Jupiter, Florida, USA.
  • Synchronicity Pharma, San Jose, California, USA.

ORCID-Profile: Priscilla Chan, Tsuyoshi Hirota, Steve A Kay

Förderung

  • Japan Society for the Promotion of Science
  • NINDS NIH HHS
  • Astellas Foundation for Research on Metabolic Disorders
  • Charlie Teo Foundation
  • NCI NIH HHS
  • NINDS
  • the NCI

Zitieren

APA

Chan, P., Nagai, Y., Wu, Q., Hovsepyan, A., Mkhitaryan, S., Wang, J., Karapetyan, G., Kamenecka, T., Solt, L. A., Cope, J., Moats, R. A., Hirota, T., Rich, J. N., & Kay, S. A. (2025). Advancing clinical response against glioblastoma: Evaluating SHP1705 CRY2 activator efficacy in preclinical models and safety in phase I trials. Neuro-Oncology. https://doi.org/10.1093/neuonc/noaf089

Vancouver

Chan P, Nagai Y, Wu Q, Hovsepyan A, Mkhitaryan S, Wang J, et al. Advancing clinical response against glioblastoma: Evaluating SHP1705 CRY2 activator efficacy in preclinical models and safety in phase I trials. Neuro-Oncology. 2025. doi:10.1093/neuonc/noaf089

BibTeX
@article{Chan2025,
  author = {Chan, Priscilla and Nagai, Yoshiko and Wu, Qiulian and Hovsepyan, Anahit and Mkhitaryan, Seda and Wang, Jiarui and Karapetyan, Gevorg and Kamenecka, Theodore and Solt, Laura A and Cope, Jamie and Moats, Rex A and Hirota, Tsuyoshi and Rich, Jeremy N and Kay, Steve A},
  title = {Advancing clinical response against glioblastoma: Evaluating SHP1705 CRY2 activator efficacy in preclinical models and safety in phase I trials},
  journal = {Neuro-Oncology},
  year = {2025},
  doi = {10.1093/neuonc/noaf089}
}
Kostenlos starten →